Clene Reports Q3 2026 Results, $3.9 Million Net Income
Clene reported Q3 2026 revenue of $56,000 and net income of $3.9 million, improving from a $8.8 million loss in the prior year. The company's operating loss was $6.3 million, with net income boosted by a $10.9 million favorable change in warrant and derivative liabilities. Clene submitted an NDA for accelerated approval of CNM-Au8 for ALS, with a Phase 3 trial planned for Q2 2027. The company has $9.9 million in cash and expects resources to last through mid-Q1 2027.

